PE20030281A1 - Formulacion liofilizada de 2-metil-tieno-benzodiazepina - Google Patents

Formulacion liofilizada de 2-metil-tieno-benzodiazepina

Info

Publication number
PE20030281A1
PE20030281A1 PE2002000636A PE2002000636A PE20030281A1 PE 20030281 A1 PE20030281 A1 PE 20030281A1 PE 2002000636 A PE2002000636 A PE 2002000636A PE 2002000636 A PE2002000636 A PE 2002000636A PE 20030281 A1 PE20030281 A1 PE 20030281A1
Authority
PE
Peru
Prior art keywords
methyl
benzodiazepine
formulation
lyophilized formulation
refers
Prior art date
Application number
PE2002000636A
Other languages
English (en)
Spanish (es)
Inventor
Kurt Douglas Dekemper
Alan Lee Fites
Steven Lamar Nail
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20030281A1 publication Critical patent/PE20030281A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
PE2002000636A 2001-07-20 2002-07-17 Formulacion liofilizada de 2-metil-tieno-benzodiazepina PE20030281A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30682901P 2001-07-20 2001-07-20
US38647402P 2002-06-07 2002-06-07

Publications (1)

Publication Number Publication Date
PE20030281A1 true PE20030281A1 (es) 2003-03-27

Family

ID=26975390

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000636A PE20030281A1 (es) 2001-07-20 2002-07-17 Formulacion liofilizada de 2-metil-tieno-benzodiazepina

Country Status (32)

Country Link
US (1) US20040176357A1 (enExample)
EP (1) EP1423124B1 (enExample)
JP (1) JP2004537546A (enExample)
KR (1) KR20040017330A (enExample)
CN (1) CN1537007A (enExample)
AR (1) AR036180A1 (enExample)
AT (1) ATE369137T1 (enExample)
AU (1) AU2002320134B2 (enExample)
BR (1) BR0211250A (enExample)
CA (1) CA2448724A1 (enExample)
CO (1) CO5540279A2 (enExample)
CY (1) CY1107759T1 (enExample)
CZ (1) CZ200484A3 (enExample)
DE (1) DE60221674T2 (enExample)
DK (1) DK1423124T3 (enExample)
EA (1) EA006506B1 (enExample)
ES (1) ES2289126T3 (enExample)
HR (1) HRP20040037A2 (enExample)
HU (1) HUP0401157A3 (enExample)
IL (1) IL159098A0 (enExample)
MX (1) MXPA04000541A (enExample)
MY (1) MY135452A (enExample)
NZ (1) NZ529667A (enExample)
PE (1) PE20030281A1 (enExample)
PL (1) PL366614A1 (enExample)
PT (1) PT1423124E (enExample)
SI (1) SI1423124T1 (enExample)
SK (1) SK182004A3 (enExample)
SV (1) SV2003001179A (enExample)
UA (1) UA80095C2 (enExample)
WO (1) WO2003007912A2 (enExample)
ZA (1) ZA200400798B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7323459B2 (en) * 2002-12-24 2008-01-29 Teva Pharmaceutical Industries Ltd. Crystal forms, methods for their preparation and method for preparation of olanzapine
HU226410B1 (en) * 2003-04-22 2008-11-28 Egis Gyogyszergyar Nyilvanosan Novel polymorphous forms of olanzapine hydrochlorides, process for producing them, use thereof and pharmaceutical compositions containing them
GB0314149D0 (en) * 2003-06-18 2003-07-23 Generics Uk Ltd Novel amorphous forms
ATE504588T1 (de) 2004-01-27 2011-04-15 Synthon Bv Stabile salze von olanzapin
WO2006076124A2 (en) * 2004-12-16 2006-07-20 Nektar Therapeutics Stable, non-crystalline formulation comprising olanzapine
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
US20070293479A1 (en) * 2006-05-18 2007-12-20 Osinga Niels J Olanzapine pharmaceutical composition
EP3735223A4 (en) * 2018-01-05 2021-10-13 Impel Neuropharma Inc. INTRANASAL ADMINISTRATION OF OLANZAPINE BY A PRECISION OLFACTORY DEVICE
PE20212195A1 (es) * 2019-03-01 2021-11-15 Eurofarma Laboratorios S A Composicion farmaceutica liofilizada de antiinflamatorio no esteroideo
HUP2100259A1 (hu) 2021-07-07 2023-01-28 Richter Gedeon Nyrt Cariprazine tartalmú szabályozott hatóanyag-leadású injekciós készítmények
CN115006406A (zh) * 2021-12-28 2022-09-06 南京清普生物科技有限公司 一种稳定的奥氮平制剂
WO2025056094A1 (zh) * 2023-09-15 2025-03-20 广州帝奇医药技术有限公司 一种冻干制剂和注射液及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0421297T3 (da) * 1989-09-30 1994-01-17 Eisai Co Ltd Injicerbare præparater indeholdende cephalosporin som lægemiddel og anvendelse deraf
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use

Also Published As

Publication number Publication date
UA80095C2 (en) 2007-08-27
WO2003007912A3 (en) 2003-05-01
CA2448724A1 (en) 2003-01-30
CY1107759T1 (el) 2013-06-19
PL366614A1 (en) 2005-02-07
CZ200484A3 (cs) 2005-01-12
CN1537007A (zh) 2004-10-13
ATE369137T1 (de) 2007-08-15
EP1423124B1 (en) 2007-08-08
EA200400211A1 (ru) 2004-06-24
DE60221674T2 (de) 2008-04-30
WO2003007912A2 (en) 2003-01-30
JP2004537546A (ja) 2004-12-16
DE60221674D1 (de) 2007-09-20
ES2289126T3 (es) 2008-02-01
HRP20040037A2 (en) 2004-06-30
AR036180A1 (es) 2004-08-18
EA006506B1 (ru) 2005-12-29
NZ529667A (en) 2006-02-24
IL159098A0 (en) 2004-05-12
HUP0401157A3 (en) 2008-01-28
CO5540279A2 (es) 2005-07-29
US20040176357A1 (en) 2004-09-09
SI1423124T1 (sl) 2008-02-29
MY135452A (en) 2008-04-30
SV2003001179A (es) 2003-07-29
AU2002320134B2 (en) 2007-04-05
KR20040017330A (ko) 2004-02-26
BR0211250A (pt) 2004-07-27
EP1423124A2 (en) 2004-06-02
HUP0401157A2 (hu) 2004-10-28
PT1423124E (pt) 2007-10-29
DK1423124T3 (da) 2007-12-03
MXPA04000541A (es) 2004-05-04
SK182004A3 (en) 2004-09-08
ZA200400798B (en) 2005-07-27
HK1066484A1 (en) 2005-03-24

Similar Documents

Publication Publication Date Title
SI1513846T1 (sl) Postopek za pripravo olanzapina form I
BR0114031A (pt) Processo para a preparação de hidratos de olanzapina e sua conversão em formas cristalinas de olanzapina
IS7319A (is) Fjölgervingar klópídógrelvetnissúlfats
MY114701A (en) Process and crystal forms of 2-methyl-thieno- benzodiazepine
WO2001079169A3 (en) Prostaglandin d2 receptor antagonists
NL300101I1 (nl) Topisch ofthalmische formuleringen die olopatadinebevatten voor het behandelen van allergische oogz iekten.
NO20072046L (no) Halogensubstituerte benzodiazepinderivater
MX2008013724A (es) Proceso para la preparacion de formas polimorficas de hidrogeno sulfato clopidrogel.
MY124786A (en) Bis-arylsulfones
HUP0103636A2 (hu) 2-Metil-tieno-benzodiazepin készítmény és alkalmazása
SI1620439T1 (sl) Novi polimorfi olanzapin hidroklorida
BR0010151A (pt) Inibidores do sistema de clivagem de glicina como antipsicóticos potenciais
WO2005090359A3 (en) Synthesis of 2-methyl-4-(4-methyl-1-piperazinyl)-10h-thieno[2, 3-b][1,5]benzodiazepine and salts thereof
AU2001216580A1 (en) Use of an epoxy-steroidal aldosterone antagonist for the treatment or prophylaxis of aldosterone-mediated pathogenic effects
ECSP034740A (es) Conjugados de pregabalina-lactosa
BR0305100A (pt) Processo para a preparação de olanzapina
AR036180A1 (es) Formulacion liofilizada que comprende 2-metil-4-(4-metil-1-piperazinil)-10h-tieno[2,3-b][1,5]benzodiazepina, su uso para la fabricacion de un medicamento, articulo de fabricacion que la comprende y proceso para prepararla
WO2003037903A8 (en) Olanzapine dihydrate-ii a process for its preparation and use thereof
WO2007050353A3 (en) Tricyclic compounds useful as oxytocin receptor agonists
AR052767A1 (es) Un procedimeinto para producir 2-metil-4-(4 metil-1-piperizanil)-10h-tieno(2,3-b)(1,5) benzodiazepina en forma pura
WO2007087555A3 (en) Novel polymorph 'form e ' of olanzapine (2-methyl-4- (4-methyl-1-piperazinyl) -10h-thieno [2, 3-b] [1, 5] benzodiazepine) and preparation of the anhydrous non-solvated crystalline polymorphic 'form i' of olanzapine from the polymorphic olanzapine 'form e'
NO20073165L (no) Fremgangsmate for fremstillingen av N-demetylolanzapin
ECSP961694A (es) Procedimeinto para preparar olanzapina (caso x - 9992m)
PE20000353A1 (es) Formulacion de 2-metil-tieno-benzodiazepina
DE602006021792D1 (de) Verfahren zur herstellung von olanzapin

Legal Events

Date Code Title Description
FG Grant, registration